Pharmaceutical sector is still in its early stages and lacks large-scale, international-standard Contract Manufacturing Organizations (CMOs) in Mauritania. Most of the country’s pharmaceutical needs are fulfilled through imports from Morocco, India, France, and China, with local companies mainly engaged in distribution, repackaging, and basic compounding.

While no full-service CMOs currently operate in Mauritania, businesses can still access pharmaceutical contract manufacturing through regional hubs in North Africa and trusted partners like Amber Lifesciences, a WHO-GMP and ISO-certified global CMO, as well as through collaborations with local importers and distributors.

CMO Pharmaceutical Landscape in Mauritania

1. Local Manufacturing Capacity
   Mauritania’s local production is limited and mainly focused on basic services rather than full-scale drug manufacturing. The key players include:
   • Importers & Distributors: Licensed companies that import and distribute finished medicines nationwide.
   • Government Entities: The state procures essential drugs for public health programs.
   • Small-Scale Production: Mostly repackaging bulk products into retail packs and basic compounding (e.g., saline solutions, ointments).

   There are no facilities in Mauritania producing APIs (Active Pharmaceutical Ingredients) or carrying out advanced dosage formulations to WHO-GMP standards.

2. Contract Services in Practice
   In Mauritania, “contract manufacturing” usually refers to partnerships with local agents who manage:
   • Importation & Regulatory Affairs: Handling Ministry of Health approvals, product registration, and permits.
   • Distribution & Logistics: Managing warehousing, cold chain supply, and delivery to pharmacies and hospitals.
   • Market Access: Supporting tenders, promotions, and market intelligence.
3. Key Challenges
   Operating in Mauritania comes with important considerations:
   • Regulatory Framework: All medicines must be registered with the Ministry of Health (Direction de la Pharmacie et des Laboratoires). While evolving, the framework is less mature than in the EU or the US.
   • Infrastructure Issues: Transportation and reliable cold chain facilities are limited.
   • Market Size: As a small, lower-middle-income country, Mauritania’s pharmaceutical market is modest.
   • Economic & Political Stability: Currency fluctuations and local conditions can impact operations.

CMO Strategic Options for Companies

Option 1: Partner with a Regional CMO in North/West Africa

The most effective approach is to contract manufacturing to a nearby hub, such as Morocco, then work with a Mauritanian distributor for local operations.

Why Morocco?

• Strong pharma base with WHO-GMP and EU-GMP certified CMOs.
• Companies like Sothema and Cooper Pharma already export across Africa.
• Geographical proximity and French-language compatibility.

Process:

• Manufacture with a Moroccan CMO.
• Partner with a Mauritanian distributor for importation, licensing, and in-country sales.

Other potential regional hubs: Tunisia and Algeria.

Option 2: Work with an International CMO + Mauritanian Partner

For specialized products like biologics, oncology drugs, or injectables, companies often rely on international CMOs in India, France, or Europe.

• The international CMO handles manufacturing.
• A licensed Mauritanian partner oversees registration, import permits, and distribution.

CMO Finding the Right Local Partner

To succeed in Mauritania, selecting a trusted local distributor is critical. Some ways to find one:

• Databases: Africa Health Business, Espacom, and trade listings.
• Trade Missions: Mauritanian Ministry of Commerce and Chamber of Commerce.
• Conferences: West African pharma events where Mauritanian importers participate.

Tip: Always check licenses, financial stability, warehouse standards, and existing client references before partnering.

Regulatory Authority in Mauritania

• Ministère de la Santé – Direction de la Pharmacie et des Laboratoires
• Responsible for medicine registration, quality control, and market regulation.
• Partnering with experienced local agents helps streamline approvals.

Conclusion
Mauritania does not yet host full-service Contract Manufacturing Organizations (CMOs). Instead, the pharmaceutical market relies on imports, distribution partnerships, and regional manufacturing hubs.

The best strategy is a two-tier model:

• Contract manufacturing with a regional or international CMO (Morocco, Tunisia, India, or Europe).
• Partner with a licensed Mauritanian distributor for regulatory approval, importation, and in-market distribution.

Amber Lifesciences Pvt. Ltd., a WHO-GMP and ISO-certified global CMO based in India, offers reliable pharmaceutical contract manufacturing solutions for companies targeting Mauritania. With expertise in essential medicines, regulatory compliance, and export logistics, Amber Lifesciences ensures international quality standards while helping businesses navigate Mauritania’s regulatory and logistical challenges.